Pasireotide, a second-generation multi-receptor-targeted somatostatin analog, which was approved for use both in patients with CD and acromegaly, suppresses not only the secretion of ACTH and GH but also of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and insulin, along with the inhibition of the incretin effect (2, 19, 21, 29). This evidence concerns the gene GH1 and acromegaly.